Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2014-09-25 Governance Information
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Governance Information Classification · 99% confidence The document is a press release announcing that Onxeo SA received the 'Argent Governance' award ('Gouvernance d'Argent') from AGEFI for its corporate governance practices. The text explicitly discusses governance, board composition, transparency, and adherence to governance codes. This content directly relates to the company's internal rules, board structure, and governance practices, which aligns perfectly with the definition for Governance Information (CGR). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2014-09-25 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that the company management team will participate in an investor forum ('Midcap Event') to meet with institutional investors and present the company. It is not a full financial report (like 10-K or IR), an earnings release (ER), or a formal proxy/voting document. Since it is an announcement about management engaging with investors regarding company strategy and pipeline, it most closely aligns with general investor relations communication. Given the options, this type of announcement, which is not a specific regulatory filing, dividend notice, or management change, falls best under the general category of Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* meetings, and it is short, it could be considered a Regulatory Filing (RNS) as a general announcement, or potentially related to Investor Presentation (IP) materials if the context implies presentation materials are being shared or referenced. However, the core content is an announcement of participation in an investor event. This is a common type of communication that often accompanies or precedes investor presentations. Given the focus on management meeting investors to present the company, 'Investor Presentation' (IP) is the most contextually relevant category, even though this specific text is the announcement of the event rather than the presentation itself. If it were purely a regulatory filing fallback, RNS would be used. Since it is directly related to investor engagement and presentation of strategy, IP is chosen over RNS.
2014-09-24 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that the company, Onxeo, will participate in the 'Midcap Event' on specific dates (October 2-3, 2014) to meet institutional investors and present its news, growth strategy, and outlook. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing detailing a specific event like a dividend or director dealing. It is an announcement about an upcoming investor relations activity where management will present company information. This aligns best with an Investor Presentation (IP) or a general announcement related to investor engagement. Given the context of presenting strategy and outlook to investors, 'Investor Presentation' (IP) is the most fitting category, even though the document itself is an announcement *about* the presentation opportunity, rather than the presentation slides themselves. However, since it details what will be presented (news, strategy, outlook) and is clearly aimed at the investment community, IP is stronger than the general fallback (RNS). The document length is short (3103 chars), suggesting it's an announcement rather than the full presentation material.
2014-09-24 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 95% confidence The document is a press release announcing the company's participation and presentation at 'InvestorDagen 2014', a Danish private investor event. It details the content of the presentation (key strengths, strategy, product pipeline) and includes standard disclaimers and contact information. This type of material, which is a summary or announcement related to an investor event presentation, fits best under Investor Presentation (IP) or potentially a general Regulatory Filing (RNS) if it were purely an announcement. Since the text describes the content of the presentation given at the event, 'Investor Presentation (IP)' is the most appropriate classification, as it conveys the information intended for investors.
2014-09-19 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release dated September 19, 2014, announcing Onxeo's participation in the 'InvestorDagen 2014' conference organized by the Danish Shareholders Association. It details the presentation given by the management team about the company's strategy, key assets (Livatag®, Validive®, Beleodaq®), and future steps. This content—a summary of management activities and presentations made to investors at a specific event—aligns best with an Investor Presentation (IP) or a general announcement related to investor relations activities. Since it is a press release summarizing the event and the presentation content, and not the presentation slides themselves, it functions as an update for investors. Given the options, 'Investor Presentation' (IP) is the most fitting category for material summarizing management's pitch to investors, even if it's delivered via a press release format summarizing the event.
2014-09-19 French
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document explicitly discloses the "Total number of outstanding shares" and "Total number of voting rights" as of a specific date (August 31, 2014), referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the capital structure and voting rights is a specific regulatory filing requirement. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it relates to capital, it is a specific disclosure of the total share count, which often falls under general regulatory reporting or major shareholding notifications. Given the options, this disclosure of the total number of shares and voting rights is most closely related to capital structure updates or major shareholding notifications. Since it is a formal disclosure mandated by market regulators about the total share count, it fits best under a general regulatory filing category if a more specific one isn't available. However, looking closely at the definitions, it is a formal regulatory disclosure about the company's capital structure (shares outstanding). It is not a Director's Dealing (DIRS), nor a general capital raising announcement (CAP). It is a mandatory disclosure of the total share count. This type of filing, often required periodically (like monthly or semi-annually in some jurisdictions) to update the market on the total number of shares eligible to vote, is a specific regulatory announcement. Since there isn't a perfect fit like 'Share Capital Disclosure', the closest relevant categories are Major Shareholding Notification (MRQ) or the general Regulatory Filings (RNS). Because it is a formal, periodic disclosure mandated by the regulator about the total share count, it is a specific regulatory filing. In many contexts, disclosures about the total number of shares outstanding are grouped with major shareholding changes or general regulatory updates. Given the options, RNS (Regulatory Filings) is the safest fallback for a specific regulatory disclosure that doesn't match the other precise categories like DIV or DIRS. However, since it is a direct disclosure of the total number of shares, which underpins major shareholding calculations, MRQ might be considered, but MRQ usually refers to *changes* in ownership thresholds. This document is a statement of the *total* outstanding shares. Therefore, RNS is the most appropriate general regulatory filing category for this specific, non-standard disclosure.
2014-09-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.